View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Bo...

Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors Fort Lee, NJ, Sept. 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the appointment of Juan Sanchez, MD, to its Board of Directors. Dr. Sanchez is a seasoned biotech executive with expertise in industry, capital markets and medicine, having most recently served as Vice President of Corporate Communications and In...

 PRESS RELEASE

Spruce Launches Saving Surge Sweepstakes Encouraging Customers to Buil...

Spruce Launches Saving Surge Sweepstakes Encouraging Customers to Build Better Financial Habits and Awarding Nearly $5,000 in Total Prizes Inaugural initiative empowers long-term financial stability through mindful saving for smart money management KANSAS CITY, Mo., Sept. 04, 2025 (GLOBE NEWSWIRE) -- In response to the growing number of Americans struggling with financial health, Spruce, the mobile banking app built by H&R Block,1 announced today the launch of its Saving Surge Sweepstakes2. Saving Surge is a six-month initiative designed to reward and encourage consistent saving habits ...

 PRESS RELEASE

Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Glob...

Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference Fort Lee, NJ, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that senior management will participate in the upcoming H.C. Wainwright Global Investment Conference. A Nuvectis corporate presentation delivered by Ron Bentsur, Chairman and Chief Executi...

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: September 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Dillard’s, Inc. Announces $0.30 Cash Dividend

Dillard’s, Inc. Announces $0.30 Cash Dividend LITTLE ROCK, Ark., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Dillard’s, Inc. (DDS-NYSE) (the “Company” or “Dillard’s”) announced that the Board of Directors declared a cash dividend of $0.30 per share on the Class A and Class B Common Stock of the Company. The dividend is payable November 3, 2025 to shareholders of record as of September 30, 2025. CONTACT:Julie J. Guymon, C.P.A. 501-376-5965

Vikash Harlalka
  • Vikash Harlalka

2Q25 Broadband Trends

What’s new: in this report we discuss one of the drivers of slower broadband growth – a rise in mobileonly households. While we do not have the data to support it, we discuss the reasons why we find it a plausible explanation for the slower industry growth. We also update our industry forecast and reprise our work on competitive positioning of the operators based on relative cNPS scores.

 PRESS RELEASE

Block Advisors Awards Six Women-Owned Small Businesses with Second Ann...

Block Advisors Awards Six Women-Owned Small Businesses with Second Annual ‘Fund Her Future’ Grant Selected from a record-setting pool of more than 8,000 applicants, this year’s recipients represent diverse industries and share a mission to serve communities on a local and global scale KANSAS CITY, Mo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- by today announces the six recipients of its second annual grant program. The program provides $100,000 in grants to women-owned small businesses. This includes one $50,000 grant and five $10,000 grants, along with one year of Block Advisors small busi...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: August 18, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Evolus Inc: 1 director

A director at Evolus Inc bought 30,000 shares at 6.816USD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: August 16, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Dillard’s, Inc. Reports Second Quarter and Year-to-Date Results

Dillard’s, Inc. Reports Second Quarter and Year-to-Date Results LITTLE ROCK, Ark., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Dillard’s, Inc. (NYSE: DDS) (the “Company” or “Dillard’s”) announced operating results for the 13 and 26 weeks ended August 2, 2025. This release contains certain forward-looking statements. Please refer to the Company’s cautionary statements included below under “Forward-Looking Information.” Dillard’s Chief Executive Officer William T. Dillard, II commented on the quarter, “We were happy to achieve a sales increase for the first time in a while and encouraged by streng...

 PRESS RELEASE

Dillard’s, Inc. to Report Second Quarter and Year-to-Date Results

Dillard’s, Inc. to Report Second Quarter and Year-to-Date Results LITTLE ROCK, Ark., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Dillard’s, Inc. (DDS: NYSE) will announce results for the 13 and 26 weeks ended August 2, 2025 tomorrow before the open of the New York Stock Exchange. Contact: Julie J. GuymonDirector of Investor Relations(501) 376-5965

SunOpta Inc: 1 director

A director at SunOpta Inc sold 47,500 shares at 6.220USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

 PRESS RELEASE

H&R Block Reports Fiscal 2025 Results and Provides Fiscal 2026 Outlook

H&R Block Reports Fiscal 2025 Results and Provides Fiscal 2026 Outlook - Delivered Revenue Growth of 4% and Earnings per Share Growth of 7% - - Returned $600 Million to Shareholders via Dividends and Share Repurchases - - Increases Quarterly Dividend by 12% - KANSAS CITY, Mo., Aug. 12, 2025 (GLOBE NEWSWIRE) -- H&R Block, Inc. (NYSE: HRB) (the "Company") today released financial results1 for its fiscal 2025 year ended June 30, 2025. "Fiscal 2025 marked another year of meaningful progress in our transformation journey, with strong revenue growth, disciplined capital allocati...

 PRESS RELEASE

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for N...

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900 The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination with EGFR and ALK inhibitors in patients with NSCLC whose cancers developed resistance to these treatments Nuvectis will hold a conference call tomorrow, Tuesday, August 12 at 8:30 AM ET to discuss the elements of the Phase 1b program and the overall market opportunity for NXP900 Fort Lee, NJ, Aug. 11, 2025 (G...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch